Td-Impfstoff Merieux / Sanofi - LARVOL DELTA

Clodivac: Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria. (clinicaltrials.gov) - P3 | N=200 | Active, not recruiting | Sponsor: IBSS Biomed S.A. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Tetanus

Clodivac: Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria. (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: IBSS Biomed S.A. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2022 ➔ Jun 2023 | Initiation date: Aug 2022 ➔ Dec 2022 | Trial primary completion date: Dec 2022 ➔ May 2023

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Tetanus